LINK LUDWIG JULY 2014 1 Continued inside > 8 |News Roundup IN THIS ISSUE Bird virus boosts boosts virus Bird effectiveness of effectiveness immunotherapy effort 14 |Q&A Melbourne-WEHI on Peter Gibbs of Ludwig of Ludwig Peter Gibbs inspiration andscience

LUDWIG LINK | JULY 2014 Director of Communications Director Steinhardt Rachel Sincerely, reading! Happy more prizes. appear, would who,it way to their areresearchers on by Ludwig made discoveries latest to cover the pages afew we aside set asalways, 13. And, page on answers their See science. impact prizes how world the around from researchers Ludwig We young asked also three scientists. of its dedication the and research of Ludwig caliber high to the as testament therapy. or Taken research to together, serve they researchers this year recognizes significant contributions awards wonby of the our Each questions. to big ask dared who scientists 13 you’ll issue Ludwig this In about read awe-inspiring. the and inspired the intrepid, to the hats collective our to tip ofopportunity usan rest the give they And it. celebrate asthey asmuch at least achievement human Prizesinspire got. of them A prize is each what race. space off a tocommercial kick one used XPrize Foundation the recently, More of aviation. business the revolutionized LETTER

from New York New from and to Paris, Lindbergh got one for flying later, ahalf and Charles century a France. in About potato famines, and popularized the ease could that a vegetable for identifying 1773 in one got Antoine-Augustin Parmentier 2 On the cover: the On Xxxxxxx of Ludwig LUDWIG LINK LUDWIG Nonpareil class A new chief Inspired immunotherapist Turbocharged team Cancer’s enemy worst Awards and distinctions Required reading Required youDid know ... with PeterQ&A Gibbs ascientist Ask A winning combination Company news nuclearThe option Break repair detectives DNA headwayMaking Clairvoyant Developmental disorders birdsOf men and Real for hope real change News roundup perfectum trium Omne notesMeeting TABLE CONTENTS OF

JULY 2014 JULY 1 1 1 1 1 2 1 1 1 1 0 9 4 3 2 2 2 1 0 0 9 8 8 7 7 6 6 5 4 4 3 3 3

LUDWIG LINK | JULY 2014 Awards and Distinctions the deadliest type of adult brain cancer. Their work in in cancer. work brain Their of adult type deadliest the to describe the genomes of multiforme, first werethe they of Health, Institutes National US the and University Duke from researchers with Working translation of discoveries into clinical applications. the and treatment, and diagnostics tumor of brain new their groundbreaking work toward the development for werehonored They science. innovative forits team recognizes interdisciplinary research an outstanding 2014 Team which AACR Award, the received Science tumors, brain malignant on focusing team of aresearch members Papadopoulous, Nick and Diaz Velculescu, Luis Ken Kinzler, Vogelstein, Victor Bert scientists Ludwig organization. to the of25 service years than more his and multiforme, glioblastoma , intractable and aggressive most the one of against fight global the in leadership his genetics, cancer in work the award, the AACR commended him for his pioneering Web cancer. giving suppress In that of genes existence the for evidence genetic direct first the publishing seminal discoveries, he is perhaps best known for many made has he Though bill. that fits Web certainly field. the on impact a major had has leadership whose research of cancer champion atrue recognizes April, in meeting AACR the at received he which award, The Research. Cancer in Achievements Extraordinary and Foti Award forLeadership Margaret for Association Cancer ResearchAmerican (AACR) eighth the received Diego’s Web Cavenee San Ludwig TURBOCHARGED TEAM TURBOCHARGED WORST ENEMYCANCER’S

3 namesake.” award’s of the accomplishments many the and awardees givenespecially gratifying the stellar group of previous Foti Award,” is Margaret Web. the receive “This said to chosen to have been honored and delighted am “I Nickolas Papadopoulos, Victor Velculescu (not pictured) Ludwig Johns Hopkins team. Vogelstein, Luis Bert Diaz, Ken Kinzler, cancer. forthis therapies new to develop race the on influence ahuge had has multiforme glioblastoma Web Cavenee Ludwig San Diego

LUDWIG LINK | JULY 2014 Awards and Distinctions therapies totherapies the clinic. cancer breast transformative several brought has who researcher cancer and oncologist adistinguished is José Committee, Advisory of Ludwig’s Scientific a member in-chief at Memorial Sloan Kettering Cancer Center and 2015. in Physician- beginning year forone serve will and AACR of the President elected been has Baselga José “Realizing the Potential of Cancer Immunotherapy.” entitled award lecture an delivered he where Diego, San in Meeting Annual AACR 38th the award during honor. the for this received He selected to be member Ludwig first the is Jedd trials. clinical field’s the in points Research in paper” a“landmark as describes AACR the what in colleagues and by Jedd published initially studies. New criteria for evaluating such responses, forstandards evaluating novel in immunotherapies clinical appropriate establish to efforts led also has Jedd diseases. manageable or curable into largely cancers lethal currently many turn help could field to the contributions continuing and of cancer. immunotherapy care in research Jedd’s clinical the improved have notably discoveries whose The Rosenthalmelanoma. Award recognizes researchers his groundbreaking contributions to immunotherapy for for AACR the Award from Memorial Rosenthal Hinda and 2014 the Richard received MSK of Wolchok Ludwig Jedd A NEW CHIEF NEW A INSPIRED IMMUNOTHERAPIST , have now become an additional focus for end forend focus additional an , have become now

Clinical Cancer Cancer Clinical

4 the association’s goal of defeating all cancers. all of defeating goal association’s the to further countries 90 some in members 34,000 than more and of directors board AACR the with work will He of the organization’s scientific journal more than 20 years andis the founding editor-in-chief for AACR the involved with actively been has He Jedd Wolchok Ludwig MSK

Cancer Discovery

.

LUDWIG LINK | JULY 2014 Awards and Distinctions of them our congratulations.” to each Iextend community, Ludwig of the behalf On researchers distinguished in their respective fields. and leaders scientific as have accomplished they all of acknowledgment awell-deserved is This research. cancer on had has work their impact profound the and to science commitment of their depth to the testament is academy into the induction director. “Their of 2014,” Ludwig’s class scientific for the Lane, David said selected scientists to haveLudwig five honor agreat is “It Weissman. Irv and Ken Kinzler, Kolodner Richard Hynes, Richard Brugge, Joan April: in meeting annual their at Academy 2014 ofthe AACR of fellows class the into scientists Ludwig five renowned inducted AACR The cancer.” of treatment and prevention the in progress advancing of mission clear the with population, patient for our trials to clinical access and research, clinical and basic of policy, integration and science regulatory including fronts, multiple on forward push Iwill community, AACR the “Together with José. AACR,” said the of president-elect as to serve honored deeply am “I NONPAREIL CLASS

5 Joan Brugge Brugge Joan Committee Ludwig Scientific Advisory José Baselga Ludwig Johns Hopkins Ken Kinzler Ludwig Harvard

Ludwig Stanford Weissman Irv Ludwig San Diego Richard Kolodner Ludwig MIT Hynes Richard

LUDWIG LINK | JULY 2014 Meeting NotesMeeting “It was more about where there is a broad interest within within interest abroad is there where about more was “It teams might work together toward common goals. the ways effective most the and teams international for developing priority of high areas on centered Jolla La in discussions The meeting. third the dominated Ludwig Major scientific areas thatpresent new for opportunities sciences. of collaborative synergistic opportunities,” Strausberg, Bob head said be might there where and Research Cancer Ludwig makeup that components the of each at scientifically happening really was away what with came “People research. clinical and basic both in progress scientific to facilitate designed is network the how and science of Ludwig scope and breadth to the group a broader 2013, introduced September in held retreat, Oxford the clinical trial concepts for consideration. further Next, promising several identified and others, the of efforts of the network’s laboratories might complement the each how discussed leaders Ludwig cells. research—stem of area Ludwig important critically asingle, on focused in 2012, Stanford Ludwig at held meeting, first The back? us holds and us frustrates what And efficiently? most together work difference?we can How biggest we makethe can How best? we do do What key four to questions: answer begin to and issues, big the discussing to continue worldwide leadership Ludwig together brought California, Jolla, La 4in April on held of set meetings, complete a perfectly of third the that Take to report wish We simply pick. your complete.”is of set three “every to mean taken be can it Wikipedia), (per Alternatively perfect.” is threes in comes that “everything above means phrase Latin the right) always is knows, (which, everybody as to Wikipedia According OMNE TRIUM PERFECTUM TRIUM OMNE

6 Bob Strausberg Web Cavenee Cavenee Web Ludwig San Diego common interest. new approaches to big issues of resulting is in together things exploring ways to accomplish and group extraordinary this is Research.Cancer power The of branches and centers of Ludwig between and among the for interaction dialogue creating in the purpose interestinga very and useful have meetings These served

LUDWIG LINK | JULY 2014 Meeting NotesMeeting Omne trium perfectum, we say. perfectum, trium Omne deaths. cancer decrease ultimately will that advances transformative achieve wehow can determine and collaborations, new foster approaches, cancer patient outcomes through innovative research to improve opportunities to explore meetings future We host will complete. werenot they scientists Ludwig for but perfect, have been might meetings three The happen.” makethem really can Ludwig how and fruition to ideas specific to how bring on focus will steps next “Our Bob. initiatives,” said building in we have interest real where and community Ludwig the Ken Kinzler Ludwig Johns Hopkins disease as a priority. a as disease a real-world on impact the shared Ludwig goal of having I attribute much of this to the collaborations and new visions. inme terms of spawning absolutely tobeen unique have Ludwig meetings The

7 News Roundup Ludwig San Diego for the treatment of glioblastoma. targets drug new yield will this that anticipate and of FOXP1, expression enhanced the by affected are genes which to identify working now are They survival. patient poor with associated is tumors glioblastoma in of FOXP1 expression elevated that found researchers the mammals, in lung and brain of the development proper forthe necessary is FOXP1 Although FOXP1. as known factor a transcription of production the boosts of microRNA-9 suppression the because occurs This proliferation. cell tumor start microRNA-9, to jump- expression, of gene regulator a suppresses EGFRvIII named receptor factor growth Research an aggressive brain cancer. Published of growth the drives that amechanism have uncovered Furnari Frank and Web Cavenee researchers Ludwig Frank Furnari CHANGE HOPE FORREAL , the study reveals how a mutated epidermal epidermal reveals amutated how study , the

March 1 March

Cancer Cancer in

LUDWIG LINK | JULY 2014 News Roundup during zebrafishdevelopment. liver, eye, intestine, and the pancreas including of organs, Rnpc3 the that show of Sciences Academy National of the Proceedings on published astudy In development. minor-class splicing produce severe abnormalities during as known aprocess in defects that have demonstrated colleagues and Heath Joan researcher Melbourne Ludwig and published mice in study, The effectively. conducted pretty them kills and cells, cancer human infects preferentially it because agent antitumor an as studied NDV being is colleagues. their and Wolchok Jedd and Zamarin Dmitriy researchers MSK by Ludwig conducted to research the effectiveness ofcancer immunotherapy,according boost could people, not but birds sickens which (NDV), tumor one withInfecting the Newcastle disease virus been hindered by the ’s tendency to long has virotherapy oncolytic because notable is This tumor. uninfected of the destruction to the led also that The combination triggered a potent antitumor response system. immune the on abrake releases antibody, which by anti-CTLA-4 followed an mice, in implanted tumors of two into one directly NDV injected was of cancers. avariety with patients in responses immune virotherapy” might dramatically enhance antitumor antibody inblockade combination with this “oncolytic that administrationsuggests of an immune checkpoint DEVELOPMENTAL DISORDERS BIRDSOF AND MEN March 5 March gene is required for the rapid growth growth rapid forthe required is gene Science Translational Medicine Translational Science in Rnpc3 regulates protein February 25 , they , they in in , 8 researchers for more than 20 years, it was recently linked linked recently was it 20 years, than formore researchers eluded has splicing minor-class of significance the Though splicing machinery. own by their eliminated are that elements sequence unique with introns of minor-class afraction contain messenger RNA splicing. Most eukaryotic genomes minor-class called aprocess through production Dmitriy Zamarin Ludwig MSK MSK Ludwig succumbed to this combined therapy in the mouse model. mouse the in therapy combined to this succumbed resistantare to treatment typically immunotherapeutic that even tumors aconsequence, As blockade. checkpoint by boosted then was system, immune to the antigens tumor, cancer of the exposed also infection which viral by induced response immune inflammatory The problem NDV by injecting directlyinto the tumor. this circumvented study current The tumors. target can they before well viruses introduced systemically disable

Ludwig MSK MSK Ludwig Jedd Wolchok

LUDWIG LINK | JULY 2014 News Roundup and partial or complete responses) at 24 weeks after 24after at responses) weeks complete or partial and disease stable (including clinicalexperienced benefit of therapy onset the low ofbefore levels VEGF relatively with 41% that found of patients researchers The Research reported in the were findings The metastasize. to grow and factor the use often tumors and vessels, blood to is new create function normal VEGF’s survival. lower and to treatment responses beforeblood treatment with ipilimumab poorer had the in (VEGF) factor growth endothelial vascular protein of levels the higher relatively had who those melanoma, late-stage with patients among that discovered Center. Cancer They Dana-Farber/Harvard and MSK at treated with the checkpoint inhibitor antibodyipilimumab MSK investigated 176 advancedpatients melanoma Ludwig from Wolchok Yuan Jedd Jianda and and Harvard of Ludwig Hodi by Stephen led ofA team researchers understood,” said Joan. fully not are that diseases to other contributes splicing minor-class that show will research our that we anticipate run, long the “In effects. wide-ranging its explaining development, during expressed of genes spectrum full splicing how anddemonstrated this pathway the shapes minor-class defective with mutant a novel zebrafish identified team her and Joan syndrome. Taybi-Linder as known disorder developmental to asevere human CLAIRVOYANT February 4 February . Cancer of Cancer issue online

9 Ludwig MSK Jedd Wolchok Ludwig Harvard Stephen Hodi treatment were not linked to treatment outcomes. during levels VEGF in changes outcomes, treatment to predict potential the had levels VEGF pretreatment Whereas point. that at benefit anyclinical experienced of levels VEGF high relatively with patients of the the ipilimumab treatment, whereas only 23%starting Ludwig Melbourne-WEHI Ludwig Joan Heath

Ludwig MSK MSK Ludwig Jianda Yuan

LUDWIG LINK | JULY 2014 News Roundup studied who had of stage 2 or higher, 2or and of stage cancer lung had who studied patient every in detected be could DNA tumor that 6 April published findings, cancer. lung for The specific is test experimental This apatient. in left tumor is there whether detect ever before, than accuracy greater with can, test DNA super-sensitive The tumors. from come that formutations of to it look parts large scan and of DNA amounts tiny detect can test new the sequencing, deep by profiling personalized forcancer CAPP-seq, Dubbed treatments. to various responds cancer apatient’s how monitor can also but of cancer presence the detects only not that test ablood have developed Alizadeh Ash and Diehn by Maximilian led Stanford at researchers Ludwig of issue cancer. bowel and the In stomach worldwide: cancers common most of the for two There’s hope new possible clinical trials and improve the outlook for outlook improve the and trials clinical possible expedite will this hope “We Matthias. said patients,” in inhibited successfully and safely be can JAK proteins exciting clinical trials have because already shown that year. each particularly is cancers “This two these with diagnosed are worldwide people million 1.7 than More studies. preclinical in cancers bowel and stomach of growth the reduced JAKs, as known proteins inhibit which drugs, The effects. fewer side with cancers these show that inhibitors Janus could kinase (JAK) help treat colleagues and Tracy Putoczki Ernst, Matthias researchers DNA DETECTIVES DNA HEADWAYMAKING Molecular Cancer Therapeutics Nature Medicine Nature in , Ludwig Melbourne Melbourne , Ludwig , indicate February 10 Ludwig Melbourne-WEHI Ludwig pancreatic cancer. and cancer esophageal cancer, breast as lymphomas, of cancer—such types forother tests developing and test The researchers are working to improve the lung-cancer cancer. 1lung stage with patients in time the half about Matthias Ernst conditions. conditions. investigated in trials for the treatment of other and aredisorders and rheumatoid being arthritis, of blood treatment forthe market the on already are cancer.” bowel and stomach with JAKinhibitors people Ludwig Stanford DiehnMaximilian

Ludwig Melbourne-WEHI Ludwig Tracy Putoczki Ludwig Stanford Ash Alizadeh

LUDWIG LINK | JULY 2014 News Roundup how these get inside. inside. get these how localization signal, and researchers have long wondered throughimported the nuclear envelope a nuclear carry actively are that proteins of all not the But characterized. well very been has pathway This signal. localization nuclear canonical the as known proteins such of sorts—on code bar molecular asequence—a detects that system into through an the nucleusactivetransport gain entry imported proteins larger of the Many work. its to do cell a inside place right to the to get needs protein Every individual patients, enabling more personalized care. which will therapies select effective be oncologists for better responses to chemotherapy. The RPS may help but rates survival patient inferior with associated are RPS low with tumors that show and cancers lung and breast with patients in RPS the validate They oflevels genes. four expression the on based is which RPS, or score, proficiency cancer therapy. They have created a recombinant of context the in pathways repair DNA of efficiency the Weichselbaum and colleagues share a methodto quantify Medicine Translational the In treatment. cancer component of both and responses to acritical is repair damage DNA So DNA. damage severely rise to cancer. Furthermore, many cancer treatments give can damage DNA repairing makewhile cells Mistakes THE NUCLEAR OPTION OPTIONTHE NUCLEAR REPAIRBREAK , Ludwig researcher Ralph Ralph researcher Chicago , Ludwig March 26 March issue of issue Science

11 Ludwig Oxford Lu Xin care. personalized enabling more patients, for individual effective be will therapies which select oncologists help The may RPS Ralph Weichselbaum Ludwig Chicago

LUDWIG LINK | JULY 2014 News Roundup Company News Company that bind and activate the protein GITR, which boosts boosts which GITR, protein the activate and bind that advance into preclinical development—two antibodies will 4-Antibody and by Ludwig CPMs developed three by Agenus, of 4-Antibody acquisition recent the With head of technology development. Skipper, Jonathan said targets,” key checkpoint against directed CPM toantibodies viable us create allowed has by 4-Antibody developed technology the with intranslational immuno-oncology expertise research Ludwig’scancer. fight “Combining system immune own apatient’s by helping diseases other and cancer to target cells of immune (CPMs), ability the boost which several monoclonal antibody checkpoint modulators developed has Ludwig 4-Antibody, with collaboration in few years, last the Over innovators. and champions its of one been has Ludwig And immunotherapy. of cancer Checkpoint inhibitor therapy is a high point in the history mutation, the : familial of in cells nucleus the in aberrantly accumulates protein why amutant explains pathway, and also team novel signal the the detecting In borne by dozens of proteins encoded by the genome. signal RaDAR pathway. aspecific recognizes pathway This the it named and nucleus, into the shuttled actively be can proteins pathway new by which a identified has Lu by Xin led researchers Oxford of ateam Ludwig Now A WINNING COMBINATION WINNING A

12 agonists and LAG-3, TIM-3 and PD-1 antagonists. PD-1 and TIM-3 LAG-3, and agonists development of other CPM including OX40 antibodies, and discovery forthe underway also are Programs combinations. in and agents of CPMs single as portfolio the to advance plan together,Working organizations the mechanism the body imposes on the immune system. abraking unlocks that antibody monoclonal CTLA-4 a and cells; infected and to cancerous responses cell T Jonathan Skipper human health. and life cellular in play proteins characterized poorly many roles the understand better scientists help and ailments several in dysfunction molecular on light shed The discovery, published 22 on May nucleus. into the it shuttle and it detect can pathway RaDAR the so protein to the asignal confers out, turns it in Cell in , could help help , could

LUDWIG LINK | JULY 2014 Ask aScientistAsk Are prizes for good science? Ludwig Johns Hopkins Johns Ludwig recognized. is being that work of the awareness public increase help also can prizes Science scientists. of group or of ascientist achievements and work the of However, asrecognition controversial. serve they to be potential have the Prizesdo yes. general, In Ludwig Melbourne career. a as to science of themselves much so give who for those asheroes,” is which gratifying scientists to “celebrate aim Valley’s by Silicon elite Prizesinaugurated Breakthrough $3 million The is valuable. rewarded and recognized formally to have research your Prize, any opportunity to aNobel up awards right From departmental-level Stanford Ludwig challenging funding climate. increasingly an in ideas cutting-edge and of risky for ‘no strings attached’ research, allowing the pursuit money provide also may prizes recipients, For the path. asacareer science highlight and asheroes scientists portray awareness, public Prizesincrease celebrated. and be recognized should discoveries Scientific NICHOLAS ROBERTSNICHOLAS KATHERINE WOODS NEWMANAARON 13

LUDWIG LINK | JULY 2014 Q&A withQ&A Peter Gibbs a passion for research that I carry with with Icarry that for research a passion had and person inspirational was an He disease. that in interest my initial sparked melanoma in interest whose Denver from professor was avisiting Robinson Bill example? you givean Can future. the in to do Iwanted what to identify and to go Iwanted where out mework helped and were difficult me invaluable guidance when times gave journey. They my scientific along me grants and but papers, also encouraged writing and projects planning including basics, research the to do how me showed and me inspired only not I workedwith people The important. are most that with you train people the but places It’s the not scientist? ayoung as trained you places were the How important needless suffering. prevent and people to help my passion be to continues was and reason important most the But for them. had she respect the and doctors spoke about my mother way was the me impressed always that things of the One them. in happens what and to hospitals exposure Ihad youngster asa her with conversations through and circle was anurse, of life. My mother entire the to observe Iwas able a farm, on up Growing medicine. particularly, and, science in interest an had always I’ve research?medical in interested you become How did idealThe doctor

dose over a number of days to shrink the the to shrink of days over anumber dose aradiation release and liver the in lodge beads The groin. the near into artery an inserted acatheter via liver into the hair, of directly ahuman width are injected the one-third about beads, radioactive tiny where treatment It’s a one-off on. early it involved Igot with and Australia, Melbourne, in developed originally therapy. Itwas SIRT isinteresting an so effective? why itwas and itis what you explain Can lifesaver. aglobal SIRT, hailed was which called treatment You acancer pioneered people. with interacted he how and him by observing counselor. alot awise just and Ilearned day. mentor to this me atrue was Bill also Ludwig Melbourne-WEHI Ludwig Peter Gibbs Gibbs Peter

14

important. that are most with you train people the but places it’s not the Bottom line,

LUDWIG LINK | JULY 2014 Q&A undergoing liver resection. I felt it showed Ifelt showed it resection. liver undergoing patients in DNA circulating around data his initial presented Bert 2010,in when Iwas visiting when all began This future. near the in patients on impact abig having to start is going I believe which Together it’s agreat partnership, of cancer. types most cancer, indeed and monitoring and treatment of colorectal detection, for the method friendly patient- and effective asamore potential great has This treatment. and screening cancer for colorectal biomarkers cancer asnoninvasive DNA tumor circulating of we’re utility the together exploring oncology, in and challenge amajor to be continues tumors monitor and to detect methods of noninvasive development The moment. at I’mthe doing thing exciting most the and collaboration It’s aterrific on cancer detection and prevention? have had efforts joint your impact the and Hopkins Johns Ludwig with collaboration your about bit alittle us you tell Can tumors. liver these target effectively more that year,each treatments need who metastases liver develop who worldwide of people of thousands hundreds to the relevant year. is particularly study This next mid reported will be results the and trial 3clinical phase international an up We’re combination. finishing a powerful quite are potentially together two the and chemotherapy, with combined safely be can that treatment of form radiation local It’s a are damaged. not tissues adjoining so liver the to is confined effect The tumors. The initial data we have are very promising promising we have are very data initial The answer. to question difficult avery That’s signs cancer? early to detect we are able and routine become tests blood before How soon forth. and back of e-mails lots with to move forward, continues work the and enough are US frequent to the trips our But data. at the looking together time particularly face-to-face, and spend more frequently, more to meet able to be great be would it but options, are viable Teleconferencing and videoconferencing distance. is the challenge biggest The researchers? Ludwig other with collaborating in challenges arethe what difference, time the Besides collaborators. fantastic have been They together to the results. understand we work then for analysis; lab to Bert’s and the samples and sending them over data we’re the Melbourne, in collecting cancer. studies pancreatic of the For each cancer. We’ve in work begun also advanced with of people care optimizing to through right screening from spectrum the covering running, and up studies wecolorectal have now seven that such of sources, range awide from funding with investment initial that to leverage able have been and by Ludwig, supported generously protocol, one with We started step. next was anatural collaboration and conversation, initial the stimulated That disease. to end-stage through right early-stage from cancer colorectal with enormous promise for helping people 15

treatment. screening and cancer colorectal biomarkers for cancer noninvasiveas tumor DNA circulating of utility the we’re exploring and together oncology,in major challenge continues to a be monitor tumors detect and methods to of noninvasive The development

LUDWIG LINK | JULY 2014 Q&A screened. In Australia it’s terrible, with with it’s terrible, Australia In screened. are 50 getting than older all Americans of half than more Roughly good: is pretty of screening uptake US, the In cancerous. become beforethey polyps byit finding evenprevent curable—and it’s most when stage atearly an disease the detect can They screening. cancer for colorectal Colonoscopies are the ‘gold standard’ of basis screening. the 30% on declined has US the in cancer ofrate colorectal the that indicating Very, data recent with cancer? colorectal for screening is How effective dollars. care of health savings major result in and lives save would it is critical; diagnosis early where types cancer other many potentially and cancer for colorectal patients we how screen in transformative be could test Ablood-based symptoms. have any wouldn’twho otherwise someone in cancer to detect screen initial promising very and It’s noninvasive asafe, having an early cancer hiding somewhere. person of that chance high there’s avery means it bloodstream the in abnormality an detect can adoctor if that indicate far so data the because breakthrough a real be Itwould physical. annual of their as part for cancer to screen test blood routine a given will be patients that years, ten next the within possibility, isfor the me cancer. exciting Most colorectal stage late- through early-stage with patients of managing part astandard become will DNA circulating measuring that five years next the in expect Iwould and

about coming forward and promoting open were very and cancer breast had Kylie and Minogue Newton-John Olivia like cancer. Entertainers colorectal had they’ve said who’ve and out come aren’t there any celebrities Australia In of adisease. awareness promoting in driver big a is definitely factor celebrity “Today” 2002. in the show on air the So on acolonoscopy had Couric Katie when dramatically jumped screening US, the In increasing awareness of screening? in factor’ ‘celebrity the is How important factor. yuck the it’s just maybe Or of fear pain. or discomfort preparation, of the because colonoscopies having delay or resist often at play, patients Ithink but of factors are lots There screened. being population 5%only eligible 10% of or the 16 critical ... critical is diagnosis where early types cancer many other potentially cancer and for colorectal screen patients in how we transformative test could be blood-based A

LUDWIG LINK | JULY 2014 Q&A longer. Some of the work we’relonger. work of the is Some doing bit alivealittle cancer advanced with rather than focusing on keeping someone and stopping people from dying of cancer difference by diagnosingcancers earlier make ahuge we can screening, and DNA we’rework tumor circulating with doing the Through on. focused very been always I’ve something That’s patients. on impact potential is the driver one number The research? your with continue you to what motivated times, difficult In late. very diagnosed are being patients many so programs, don’t have any screening worse,matters many of these countries To type. make tumor any other than more cancer asaspike up forshowing colorectal poor food choices, smoking—and it’s lifestyle, West—sedentary of the bits bad These countries have adopted some of the cancer incidence, it’s now number one. of in terms or six five number to be used it where places In dramatically. increasing it’s of Asia parts in And increasing. but elsewhere in the world it’s actually is which greatnews, is declining, deaths cancer of colorectal number the US the In rates? why haven’t but survival declined, incidence rates have stomach cancer—never bowel cancer. or asabdominal it report media the and public, in it to mention reluctant very are cancer colorectal with across come I’ve few celebrities the But measures. preventive these in interest stimulated which screenings, and mammograms cancer diagnostics. in breakthrough amajor be would really That impact. greater afar with cancer to detect test screening a new cancer. bowel with I’d like to develop particularly death, life and between year. difference each the be can They of lives thousands save and stage early at avery cancers detect can methods of recovery. screening Current chances the better the them, we get earlier The late. too it’s often symptoms, clinical show cancer. cancers Once fighting in are crucial treatment and diagnosis Early the future? in you like would to accomplish What up. to come for wait opportunities just not and along you go family—as especially are important— that things for the time You doesn’t. it make and have to plan inevitably up, but will open time free and hurdle this you’ll crisis or this past get maybe that sense false havealways this one and then another one comes up. You disappear. never YouDeadlines past get done. to get need that things always There’re you’re finished. is never doing the work because areongoing Conflicts family? and work to commitments your you balance How do time. first for the presented was data DNA tumor 2circulating stage the when year this meeting Oncology of Clinical Society American at the exciting was it quite Ithink and publication, and of presentation point to the getting 17

cancer … ofdying frompeople and stopping cancers earlier by diagnosing huge difference we make can a and screening, tumor DNA circulating with doing work we’re Through the

LUDWIG LINK | JULY 2014 Q&A reduce inflammation.Other research has helps aspirin and development cancer in role underlying an plays inflammation unclear. are still this does it We know by which cancer, mechanisms the but of risk the reduce can it term long the over that showing of studies a number there’vebeen In years, recent effects. are side there any drug with and drug isYou a aspirin that have to remember potential illnesses? to day ward off itevery taking be we all shouldn’t drug, awonder really is If aspirin medication. preventive asaroutine aspirin up opening potentially aswell, cancers multiple and cancer of colorectal risk the in areduction see definitively we can I’m and 2018, hoping in available will be study of the results astroke. Initial cause can which brain, the in aswell asbleeding stomach the in bleeding cause can ratio, asaspirin benefit risk- what’s the been always has question and other diseases of aging. But the big stroke, dementia attack, of heart risk the reduce can it aspirin: to take reasons other of cancer, are lots There by to 30 40%. colorectal including of cancers, many risk the reduce markedly can aspirin that 70 older. and suggest aged data Early people healthy in risks the outweigh of aspirin benefits the whether determine to designed trial clinical randomized international is afive-year (ASPREE) Elderly the in Events Reducing in Aspirin itto accomplish? you expect what and is this what you study. explain Can ASPREE You’re the on investigator lead the makes a difference. makes adifference. that into it something turn potentially and new something start and path bold a to take generation younger the inspire those research stories that motivate and stories of success and the impact of It’s those inspirational. share. That’s to story have afantastic and things self-belief, great achieve they over time success, but with persistence and ongoing for promise don’t much show think others many that areas in work who People who’ve by it themselves. done individuals than more much me inspire who ones They’re the worked asateam. who’ve and People shared collaborative. who’ve People been Iadmire. that who’ve away in it People done things. who’ve great People achieved People. again?were 21 you ifyou inspire would what or Who available. become trials clinical ongoing of multiple results asthe so or decade next the in answered will be questions these many of think I abilities. fighting cancer- arole its in play could clotting blood to reduce aspirin’s that shown ability 18

LUDWIG LINK | JULY 2014 Q&A groups of Odisha in partnership with local doctors. This is along- is This doctors. local with partnership in Odisha of groups dentists and teachers from Melbourne to work among tribal doctors, of team amultidisciplinary led he efforts, previous on 2009, building In Calcutta. of slums the and Odisha of state the multiplespearheaded in medical relief India, including efforts in made impressive contributions to global health. Elgene has also has Hippocrates—he about bit the of But—apropos at Dana-Farber.facility acore become now has that mice in cancers breast derived patient- of aplatform established and cancers, breast treat to researched underlying cancer biology and novel approaches he There Brown. Myles and Winer Eric of mentorship the under School Medical Harvard and Institute Cancer Dana-Farber the at years four spent he fellowships, postdoctoral Council Research Medical and Health National 2011 and Victoria Fulbright 2010 the Awarded heart. to advice this taken have to seems Lim, Ludwig Melbourne’s newest hire, physician scientist Elgene them.” to assistance full give to straits, financial for nothing...and if there’s to an help opportunity in someone Hippocrates urged to doctors “sometimes give your services do is invaluable. you’re when times sure to what quite not at help and advice their to seek able Being issues. of the understanding in-depth an don’t have they evenif you, to mentor you around of people types to have those off. ideas to bounce board It’sessential asasounding to like act around him people to have helpful it’s very and counsel, wise of asource is still admire, and respect your own. Tony Burgess, someone I greatly You’re advice. and help on increasingly to offer you, you guide you to and inspire above aren’t people asmany there is that things older, you get sadder As of the one DID YOU KNOW…

ask how they can make the biggest impact. biggest make the can they how ask and back to step researchers all of their for short-term gains: they encourage isn’t Ludwig looking organizations, other and Unlikedon’t luxury. have industry this of my Many colleagues results. immediate for need the or deadlines without andopportunities conduct my research unique to pursue freedom the me given have connections and Ludwig’s support to share? you’d that else like anything there Is 19 lifestyle intervention strategies. and therapeutic novel evaluate to and therapies, hormonal of effects systemic long-term and patients these in disease the research clinic to study recurrence patterns of breast cancer mouse models. He has established an endocrine cancer and the evaluation of novel therapies in patient-derived breast in signaling hormone on afocus with Melbourne, Ludwig Elgene currently leads translational breast cancer research at Australia. in care health accessing in barriers many face who Melbourne, in seekers asylum to aphysician as volunteered also has He care. health and cancer of model viable economically and appropriate aculturally establish to agoal with endeavor term

LUDWIG LINK | JULY 2014 Required Reading RR, ConnellRR, PP. Weichselbaum TE, Darga B, Budke HL, Logan IM, SP, Pashtan Pitroda to chemotherapysensitivity repair proficiencyand tumor expression score correlates with gene pathway repair DNA 2014 26 Mar TranslationalScience Medicine Ludwig Chicago P. Bruggen der PJ, van P, Courtoy Smissen Der Van J-F, Baurain K, J,Thielemans Carrasco J-L, V, Squifflet Stroobant G, Wieërs R, Bigirimana N, Demotte infiltratinglymphocytes freshly isolated human tumor– of functions the corrects GM-CT-01 galactomannan with treatment A short 2014 Clinical Cancer Research T. C, Boon J,Uyttenhove Snick Van J, JF, Dyson Baurain N, Baren van F, Brasseur B, Lethé I, Jacquemart Bourdeaux C, LurquinC, immunotherapy mice as a model for cancer female by grafts skin male leading to rejection of accepted Local immunostimulation 2014 4 March USA Sciences of Academy National the of Proceedings Brussels Ludwig April 21 April

Stainier DY, Heath JK. DY, Heath Stainier GJ, Lieschke SM, Grimmond HA, Field EA, Ober H, Verkade SJ, AY, Ng Y, AJ, Wilkins Trotter Boglev MC, Keightley K, Doggett RM, Lardelli N, Cloonan S, Markmiller development zebrafishtranscriptome during the shapes splicing class Minor 25 2014 February USA Sciences of Academy National the of Proceedings Ludwig Melbourne F, G. Coukos Benencia P, MD, Lal Feldman IS, Hagemann RR, T, Lastra LP, Garrabrant SP, GT, Wang Santoro Motz tumors barrier promoting tolerance in immune aselective establishes Tumor endothelium FasL print) of 2014 ahead 4(Epub May Nature Medicine Lausanne Ludwig T, Kunkel LM, Fletcher JA. Ordog M, Rijn de van GD, Demetri CP, Raut X, Guo CDM, Fletcher CR, Antonescu Fox EA, Z, Gu BS, J,Fletcher Henze J-C, Lee G, Y, Shen M, Eilers Zhu RR, Bennett A, Y,Wang Marino-Enriquez with myogenic programs suppressor in human cancers Dystrophin is a tumor print) of ahead (Epub 2014 4 May Genetics Nature Ludwig Harvard

20 Cancer Immunology Research Cancer Immunology JP. Allison JD, T, P, Wolchok Palese Merghoub M, Mansour JS, Park SK, Subudhi Zamarin D, Holmgaard RB, immunotherapy checkpoint blockade immune to resistance overcomes systemic tumor Localized virotherapy oncolytic 2014 5 March TranslationalScience Medicine MSK Ludwig M. TJ, Ernst Phesse PM, D, Waring J,Huszar Elzer R, Farid S, Thiem T, Putoczki M, EC, Buchert Stuart gastrointestinal tumors in mice inhibits progressionactivity of Therapeutic inhibition of Jak 2014 February Wolchok JD, Hodi FS Hodi JD, Wolchok DB, J,Page P,Wong Naidoo X, Wu Philip KS, D, Panageas Kuk S, Tandon Z, J,Dong J,Zhou Yuan treated with ipilimumab advanced melanoma patients in survival overall and response is associated with clinical Pretreatment serum VEGF 4 2014 February Therapeutics Cancer Molecular .

Ludwig SanLudwig Diego AY. Rudensky JA, Stamatoyannopoulos Y, Feng RM, J, Samstein Veeken der van A, Arvey in regulatory T cells Foxp3 factor transcription the by repression of chromatin bound Inflammation-induced 2014 13 April Nature Immunology Alizadeh AA, Diehn M. Diehn AA, Alizadeh Jr, BW Loo JB, Shrager RE, Merritt HA5, Wakelee JW, Neal CL, Liu LA, JF, Modlin NC, Eclov Wynne SV, To J, Bratman AM, Newman coverage patient broad with DNA tumor for quantitating circulating An ultrasensitive method print) of ahead (Epub 2014 6 April Nature Medicine Stanford Ludwig Cavenee WK. FB, CW, Furnari Brennan DH, Gutmann R, Emnett M, C, Li Zanca CM, Croce S, Volinia GG, Gomez glioblastoma tumorigenicity upregulates FOXP1 to enhance signaling EGFR mutant by Suppression of microRNA-9 2014 1 Mar Cancer Research

LUDWIG LINK | JULY 2014